Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023PRNewsWire • 11/07/23
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA NephropathyPRNewsWire • 10/27/23
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023PRNewsWire • 10/19/23
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndromePRNewsWire • 10/05/23
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023PRNewsWire • 09/29/23
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EUPRNewsWire • 09/28/23
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxibPRNewsWire • 09/27/23
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?Zacks Investment Research • 09/22/23
Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in TokyoPRNewsWire • 09/19/23
Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection PointSeeking Alpha • 09/03/23
FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyPRNewsWire • 08/18/23
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetPRNewsWire • 08/15/23
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibPRNewsWire • 07/13/23
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?Zacks Investment Research • 07/06/23
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®PRNewsWire • 06/21/23
Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )PRNewsWire • 06/21/23